US Brain Cancer Diagnostic Market Market Report 2023 to 2030

US Brain Cancer Diagnostic Market Analysis

$ 3999

US Brain Cancer Diagnostics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2033. The market for Brain Cancer diagnostics is expanding as a result of increasing incidence of the Brain Cancer. There have been significant developments in imaging techniques such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) which are driving the growth of Brain Cancer Diagnostics market. Some of the key players in the global Brain Cancer Diagnostics Market Thermo Fisher Scientific Inc., Siemens Healthineers AG, GE Healthcare, MDxHealth, NantOmics,Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., Neusoft Medical Systems.

ID: IN10USHS027 CATEGORY: Healthcare Services GEOGRAPHY: US AUTHOR: Dr. Nensi Savani

Buy Now

US Brain Cancer Diagnostic Market Executive Summary

US Brain Cancer Diagnostic Market is valued at around $688.8 Bn in 2022 and is projected to reach $4516.7 Bn by 2030, exhibiting a CAGR of 26.5% during the forecast period 2023-2030.

The Brain Cancer Diagnostics Market refers to the market for tools and methods used to diagnose Brain Cancer, which is a result of cancer cell growth in brain. These cells form tumor which can be slow-growing or fast-growing depending on the type of tumor. The market includes software and platforms for analysing and interpreting the findings of diagnostic tests, imaging methods, and biomarkers used to detect the disease.

Around 330,000 children and adults were diagnosed with the cancer of Central Nervous System in which Brain Cancer contributes major part, which has contributed to the growth of the global market for Brain Cancer diagnostics in recent years. Advances in diagnostic technologies, such as the creation of more precise and sensitive biomarkers and imaging methodologies, are also driving the market.

Pharmaceutical and biotechnology firms like Thermo Fisher Scientific Inc., Siemens Healthineers AG, GE Healthcare, MDxHealth, NantOmics, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi Ltd., Neusoft Medical Systems are some of the major players in the Brain Cancer diagnostics market.

Brain Cancer is diagnosed using a variety of diagnostic procedures and tests, including cognitive assessments, imaging examinations like MRI and PET scans, and cerebrospinal fluid (CSF) studies. For use in Brain Cancer diagnosis, biomarkers including and CTC and cfDNA levels in the blood, as well as brain imaging methods MRI and PET scans are also being improved.

Increasing incident and rising awareness of Brain Cancer and early detection are projected to fuel the market for diagnostics for the condition in the years to come. The market still has difficulties with regard to obtaining regulatory permission, high cost for diagnostic procedures and therapies, as well as limited treatment options and accuracy of the diagnostic procedures.

Market Dynamics

Drivers of US Brain Cancer Diagnostics Market:

Growing Incidence and of Brain Cancer: As the world's population ages incidence of Brain Cancer is increasing and other risk factors like ionizing radiation, environmental toxins and genetic predisposition also contributes to it. This is raising the demand for diagnostic methods and technologies that can successfully identify the illness.

Advancement in technology: The expansion of the Brain Cancer Diagnostics Market is being driven by advancements in diagnostic technologies, which include the creation of more sensitive and specific biomarkers, imaging methods, and genetic testing.

Increasing Healthcare Expenditure: The market for Brain Cancer diagnostics is expanding as a result of rising healthcare spending in both developed and developing nations. This demand is fueling the development of better diagnostic tools and methods for the early detection and accurate diagnosis of Brain Cancer.

Government measures and supporting: Governments throughout the world are supporting research to create efficient diagnostic tools and techniques and taking measures to increase awareness of Brain Cancer, which is also propelling the growth of the Brain Cancer Diagnostics Market.

Growing Interest in Personalised Medicine: In the years to come, it is anticipated that the interest in individualised medicine will continue to fuel the development of diagnostic tools and methods that can pinpoint specific biomarkers and genetic variants linked to Brain Cancer.

Rising demand for non-invasive diagnostic procedures: Non-invasive diagnostic methods for brain cancer are more frequently used by patients and doctors because they are more accurate, safe, and comfortable than invasive methods.

Developments in Brain Cancer Diagnostics Market:

The market for Brain Cancer diagnostics is always changing due to new discoveries and improvements in science and technology. Recent market developments include the following:

New Biomarkers: Researchers are creating new biomarkers, such as plasma-based biomarkers which will increase the precision in diagnosis of Brain Cancer. It will detect CTCs and cfDNA in the blood and it is less invasive method for the diagnosis of Brain Cancer.

Advancements in imaging techniques like MRI and PET scans will improve accuracy of the diagnosis. These imaging techniques allow seeing exact location and extent of cancer, it also helps to detect any abnormal activity that indicate the presence of cancer cells.

AI-Powered Diagnostics: To analyze big data sets and find patterns that can help in the early identification and precise diagnosis of Brain Cancer, AI-powered diagnostic tools are currently being developed. Compared to conventional techniques, these instruments should offer more effective and precise diagnoses.

Blood-Based Diagnostics: Scientists are working to create blood-based diagnostic techniques that can identify particular biomarkers linked to Brain Cancer, offering a less invasive and more accessible diagnostic option.

Genetic testing integration: To discover genetic variants linked to the condition, genetic testing is being incorporated into diagnostics for Brain Cancer. Using this data, one can identify those who are more likely to contract the illness and establish individualised treatment regimens for them.

Given that they increase the precision and accessibility of diagnostic tools and techniques for Brain Cancer, these innovations are anticipated to propel the expansion of the market for Brain Cancer diagnostics.

Notable deals in Brain Cancer Diagnostics Market:

In November 2022, Siemens Healthcare GmbH unveiled two newest magnetic resonance tomographs for clinical and research usage. Both scanners will be highly effective at identifying the smallest body structures with greater clarity due to their high field strengths and strong gradient performance.

In November 2022, BD stated that it would give Valley-Mount Sinai Comprehensive Cancer Care a donation of USD 652,000 which will help to boost inclusion, equity, and diversity in cancer clinical trials.

Key players

GE Healthcare Siemens Healthineers AG F. Hoffmann-La Roche Ltd. Abbott Laboratories Thermo Fisher Scientific, Inc. Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Illumina, Inc. Quest Diagnostics Myriad Genetics, Inc.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For US Brain Cancer Diagnostics Market

By Type:

Gliomas
Meningioma
Acoustic Neuroma
Astrocytoma
Oligodendroglioma
Ependymomas?
Others

By Diagnostics:

Brain Imaging
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Computed Tomography (CT)
- Other Imaging Techniques
Cerebrospinal Fluid (CSF) Test for Brain Cancer
Biopsy
Neuropsychological testing
Blood tests for biomarkers and genetic mutation

By End-user:

Hospitals
Specialty clinics
Diagnostic centers and research institutes
Ambulatory surgical centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.